Pomarza 1, 2, 3 & 4 1,0 mg, 2,0 mg, 3,0 mg & 4,0 mg Gelatin Capsules
PDF Leaflet Revision Date: 03 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with multiple myeloma after prior therapies.
Dosage (summary)
4 mg orally once daily on days 1-14 for PBd regimen; 4 mg/day on days 1-21 for Pd regimen.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects expected.
Key Drug Interactions
- CYP1A2 inhibitors
- CYP3A4 inducers
- Dexamethasone
Contraindications
- Hypersensitivity to pomalidomide
- Pregnancy
- Lactation
- Females of childbearing potential not meeting criteria
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
- Dizziness
- Rash
Counselling Points
- Use effective contraception
- Report signs of infection
- Avoid driving if affected by dizziness
Serious warnings
- Severe birth defects
- Venous thromboembolism
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Pomarza 1, 2, 3 & 4 1,0 mg, 2,0 mg, 3,0 mg & 4,0 mg Gelatin Capsules professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
